Sponsored Breakfast Sessions
Sponsored breakfast sessions will be held on Friday 11th August from 0730 – 0815hrs.
Lessons learnt about ARNI; recent publications and practical use
Join us with your colleagues in discussing how clinical experience with the Angiotensin Receptor Neprilysin Inhibitor (ARNI) has shaped heart failure management in Australia and worldwide. Recent sub-analyses from the PARADIGM-HF trial will be presented and a deep dive into some practical insights on how to integrate ARNI into the clinical care of heart failure patients with reduced ejection fraction.
Speaker: Associate Professor John Atherton, Cardiologist, Director of Cardiology at the Royal Brisbane and Women’s Hospital and Associate Professor, Department of
Medicine, University of Queensland
Room: Meeting Rooms 1 and 2
The Great Debate – PCSK9 inhibitors: Can we afford not to have them?
In recent years, PCSK9 inhibition to lower LDL cholesterol levels has quickly moved from being an interesting research question to a clinical reality. The evidence base for this therapeutic class is expanding rapidly, as clinical trials programs reveal the details of the efficacy and safety profile for these agents. The next key question is whether we can afford not to have them.
Please join us at the Amgen-sponsored breakfast symposium to hear two of Australia’s leading lipid experts explore opposing viewpoints. This topical subject is meant to stimulate discussion and generate food for thought.
Presenting for the affirmative case: Professor Tony Keech, NHMRC Clinical Trials Centre, Royal Prince Alfred Hospital
Presenting for the negative case: Professor Steve Nicholls, University of Adelaide, South Australian Health & Medical Research Institute
Chair: Professor Gerald Watts, University of Western Australia, Royal Perth Hospital
Room: River View Room 5
Ask the Experts: management of thrombosis in special patient populations
The ripple effect of atrial fibrillation and anticoagulation
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia observed in medical practice1 and is increasing in prevalence2. Diagnosis starts a life-long ripple effect of treatment options and management strategies. Approximately 200,000 Australians diagnosed with atrial fibrillation (AF) are treated with oral anticoagulants to manage thrombotic stroke risk2. Well-considered clinical decisions taken for these patients is supported by evidence from RCT and increasingly large retrospective observational studies.
Speakers: Associate Professor John Amerena, Dr Andrei Catanchin, Professor Anthony Brown
Chair: Dr Michael Davis
Room: River View Room 4
Unravelling Real World Data – what should we believe?
Randomised controlled trials provide an accurate understanding of the effect of an intervention in a well-defined patient group under controlled circumstances. Observational studies provide an understanding of real-world care and its impact, but can be biased due to uncontrolled factors. Randomised controlled trials are given a higher evidence grade but observational studies provide important clinical insights. In view of the topical nature of real-world data in cardiology at the moment, our speakers will take a deep dive into the data to offer their critique and consider where confounding factors may influence the interpretation of real-world data analyses.
Speakers: Associate Professor Paul Gould, Princess Alexandra Hospital (QLD), and Dr Bradley Wilsmore, John Hunter Hospital (NSW)
Chair: Professor Rukshen Weerasooriya, AF Abalation Clinic Nedlands (WA)
Room: Meeting Room 3